Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04731935
Other study ID # SBM-OWP-04
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 18, 2021
Est. completion date May 26, 2021

Study information

Verified date January 2021
Source Spark Biomedical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate whether tAN via the tragus (vagal) and auriculotemporal (trigeminal) nerve pathways results in a clinically meaningful reduction in opioid withdrawal symptoms.


Description:

This study is designed as a pilot, single-center, non-randomized, uncontrolled, clinical trial in which subjects will be consented, receive a baseline assessment, and receive tAN treatment and assessment every day during their 3 to 5-day detox treatment. Use of opioid-based medication assisted therapy (MAT) will not be permitted at any point during the study. Use of non-opioid-based MATs (i.e. comfort or rescue medications) will not be permitted until after the subject has completed the 60 minute COWS assessment to ensure changes in COWS score at 60 minutes are only the result of tAN therapy.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date May 26, 2021
Est. primary completion date May 26, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Current opioid dependence; prescriptive or non-prescriptive - COWS score is = 13 or in the opinion of the investigator the subject is in moderate to severe withdrawal - 18-65 years of age - English proficiency - Participants must be able to provide informed consent and function at an intellectual level sufficient for study requirements Exclusion Criteria: - Current evidence of an uncontrolled and/or clinically significant medical condition - History of seizures or epilepsy - History of neurological diseases or traumatic brain injury - Participants using long-acting opioids such as methadone or buprenorphine for a period of five or more consecutive days prior to enrollment - Recent suicide attempt leading to current hospital admission or continued expressed suicidal ideation - Presence of devices (e.g., pacemakers, cochlear prosthesis, neurostimulators) - Abnormal ear anatomy or ear infection present - Women of childbearing potential not using adequate contraception as per investigator judgement or not willing to comply with contraception for the duration of the study - Females who are pregnant or lactating - Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Study Design


Intervention

Device:
Sparrow Therapy System
Transcutaneous auricular neurostimulation

Locations

Country Name City State
United States Recovery Unplugged Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
Spark Biomedical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Heart rate variability measured by R to R interval Mean change from baseline to Days 2-5 in heart rate variability measured by R to R interval. Days 2-5
Other Patient Health Questionnaire (PHQ-9) Mean change in depression symptoms measured by Patient Health Questionnaire (PHQ-9) total score from baseline to Day 5. The PHQ-9 is a nine-item depression scale based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV. Each of the nine items is rated on a 0 (not at all) to 3 (nearly every day) scale. A total score is calculated by summing the nine items. Scores range from 0 to 27 and higher scores indicate a higher degree of depression. Day 5
Other Post-Traumatic Stress Disorder (PTSD) Checklist for DSM-5 (PCL-5) Mean change in PTSD symptoms measured by the PTSD Checklist for DSM-5 (PCL-5) total symptom severity score from baseline to Day 5. The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Each of the 20 items is rated on a 0 (not at all) to 4 (extremely) scale. A total symptom severity score is calculated by summing the 20 items. Scores range from 0 and 80 and higher scores indicating a higher degree of PTSD symptomology. Evidence suggests that a10-20 point reduction in score represents a clinically significant change in PTSD symptoms. Day 5
Other World Health Organization Quality of Life - BREF (WHOQOL-BREF) Mean change in WHOQOL-BREF domain scores (physical health, psychological health, social relationships, environment, and overall QoL/general health) from baseline to Day 5. The World Health Organization Quality of Life - BREF (WHOQOL-BREF) is a 26-item, self-report questionnaire which assesses 4 quality of life domains: physical health, psychological health, social relationships, and environment. In addition, there are 2 items that measure overall quality of life and general health. Subjects rate how much they have experienced each item in the preceding 2 weeks on a 5-point Likert scale ranging from 1 (not at all) to 5 (completely). Domain scores are scaled in a positive direction with higher scores denoting higher quality of life. Raw domain scores will be converted to a 0 to 100 scale. Day 5
Primary Clinical opiate withdrawal scale (COWS) score Mean percent change in clinical opiate withdrawal scale (COWS) score from baseline to 60 minutes after start of tAN therapy. The COWS is an 11-item scale with a score range between 0 and 48. Total score is the sum of all the items and a higher score indicates more severe withdrawal symptoms. Scores between 5 and 12 indicate mild withdrawal, scores between 13 and 24 indicate moderate withdrawal, scores between 25 and 36 indicate moderately severe withdrawal and scores greater than 36 indicate severe withdrawal. A COWS score reduction of 15% or greater for a given individual is considered clinically significant. 60 minutes
Secondary Clinical opiate withdrawal scale (COWS) score Mean percent change in COWS score from baseline to 30 minutes after start of tAN therapy. 30 minutes
Secondary Clinical opiate withdrawal scale (COWS) score Mean percent change in COWS score from baseline to 120 minutes after start of tAN therapy. 120 minutes
Secondary Clinical opiate withdrawal scale (COWS) score Mean percent change in COWS score from baseline to Days 2 through 5 after start of tAN therapy. Days 2-5
See also
  Status Clinical Trial Phase
Recruiting NCT04157062 - An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder N/A
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Completed NCT04505540 - Start Treatment and Recovery for Opioid Use Disorder N/A
Completed NCT03065049 - Transforming Recovery Through Exercise and Community N/A
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Active, not recruiting NCT04650386 - Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients N/A
Completed NCT03715634 - Study of a Novel Subcutaneous Depot Formulation of Buprenorphine Phase 1
Enrolling by invitation NCT04991974 - Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine Phase 2/Phase 3
Completed NCT04122755 - Single Ascending Dose Study of ALA-1000 Phase 1
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Recruiting NCT05049460 - Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder N/A
Recruiting NCT05028998 - COVID-19-Related Opioid Treatment Policy Evaluation
Completed NCT05047627 - Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder N/A
Active, not recruiting NCT04129580 - reSET-O RCT (Randomized Controlled Trial) N/A
Recruiting NCT03923374 - Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
Completed NCT04464421 - SMART Effectiveness Trial N/A
Suspended NCT02687360 - Imaging the Effects of rTMS on Chronic Pain N/A
Completed NCT04056182 - Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment Phase 2